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a b s t r a c t
The aim of this study was to identify proteins that could inhibit the activity of the peptide sequence rep-
resenting the N-terminal of the surface protein gp41 of HIV, corresponding to the fusion peptide of the
virus (HIV-1 FP). To do this we synthesized and studied 58 peptides corresponding to the envelope pro-
tein E1 of the hepatitis G virus (GBV-C).
Five of the E1 synthetic peptides: NCCAPEDIGFCLEGGCLV (P7), APEDIGFCLEGGCLVALG (P8), FCLEGGCL
VALGCTICTD (P10), QAGLAVRPGKSAAQLVGE (P18) and AQLVGELGSLYGPLSVSA (P22) were capable of
inhibiting the leakage of vesicular contents caused by HIV-1 FP. A series of experiments were carried
out to determine how these E1 peptides interact with HIV-1 FP. Our studies analyzed the interactions
with and without the presence of lipid membranes. Isothermal titration calorimetry revealed that the
binding of P7, P18 and P22 peptides to HIV-1 FP is strongly endothermic, and that binding is entropy-dri-
ven. Gibbs energy for the process indicates a spontaneous binding between E1 peptides and HIV-1 FP.
Moreover, confocal microscopy of Giant Unilamellar Vesicles revealed that the disruption of the lipid
bilayer by HIV-1 FP alone was inhibited by the presence of any of the five selected peptides.
Our results highlight that these E1 synthetic peptides could be involved in preventing the entry of HIV-
1 by binding to the HIV-1 FP. Therefore, the continued study into the interaction between GBV-C peptides
and HIV-1 FP could lead to the development of new therapeutic agents for the treatment of AIDS.
 2011 Elsevier Inc. All rights reserved.
1. Introduction
In recent years, synthetic peptides have attracted a great deal of
attention in the multidisciplinary and emerging field of nanobio-
medicine [1–3] due to the chemical diversity which can be toler-
ated within these nanostructures, their ease of synthesis, their
high purity and their low production costs. The multiple applica-
tions of these compounds include their use in research, diagnosis
and the treatment of viral infections such as AIDS and hepatitis
[4–7].
Significant progress has been made in the treatment of human
immunodeficiency virus (HIV) infection, but we are still far from
the end of the battle against this disease. Current therapy consists
of complex treatments of nucleoside analogs, non-nucleoside re-
verse transcriptase inhibitors, and viral protease inhibitors aimed
at specific steps of the HIV replication cycle. These drugs target
with high specificity, but caution should be exercised because
rapid virus turnover in HIV infection can result in the emergence
of resistant mutations and subsequent treatment failure [8,9].
However, the natural history of hepatitis G virus (GBV-C) infection
is, at present, not fully understood and its potential to cause hep-
atitis in humans is questionable [10].
The GB virus C (GBV-C) was recently investigated in the context
of HIV infection, because hepatitis virus infections are very fre-
quent in patients suffering from HIV as they have similar transmis-
sion routes. Infection with the hepatitis B (HBV) or C (HCV) virus
on AIDS patients has been associated with an impaired survival,
and these patients often die from liver failure instead of AIDS
[11]. In contrast, previous studies have suggested that people co-
infected with HIV and GBV-C exhibit delayed progression of HIV,
indicating a beneficial influence of GBV-C on patients with HIV
infection [12]. Based on a co-infection model, GBV-C may inhibit
HIV by inducing chemokines, down-regulating HIV co-receptor(s),
influencing cytokine profiles, and having other as yet undefined ef-
fects on the host lymphocytes [12,13]. However, the mechanism
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responsible for the beneficial effect that the GBV-C virus exerts on
the course of infection caused by HIV has yet to be fully defined.
Jung et al. [14] demonstrated that cells transfected with either
infectious RNA or a deletion mutant that expressed the N-terminal
third of the polyprotein (including the E1 and E2 coding regions)
resulted in inhibition of HIV replication, increased the release of
chemokines, and decreased the surface expression of CCR5 com-
pared to cells transfected with antisense GBV-C RNA. This indicates
that the envelope proteins may be involved in the inhibition of HIV
replication.
Recently, we described certain E2 GBV-C domains that interfere
with the HIV-1 FP-vesicle interaction, decrease the cellular mem-
brane fusion, and interfere with the HIV-1 infectivity in a dose-
dependent manner [15].
Taking into account the attractive properties of synthetic pep-
tides and the possible relation between the envelope GBV-C pro-
teins and the inhibition of HIV replication, we studied the
capacity of GBV-C E1 peptide sequences to inhibit the interaction
and destabilization process of membranes induced by the fusion
peptide (FP) of HIV-1. To achieve this, 58 E1 peptides from GBV-
C were synthesized and characterized.
Recent studies have reported the importance of leakage exper-
iments or isothermal titration calorimetry studies [16–19] in
understanding the membrane interacting properties of synthetic
peptides. Thus, several biophysical techniques were used to cover
different aspects of GBV-C peptide/HIV-1 FP interaction in the
presence and absence of lipid vesicles. As a first indication of the
ability of GBV-C sequences to inhibit pore formation caused by
HIV-1 FP we chose the leakage of the vesicular content assay
[16,17,20]. From the results of this initial test, five sequences were
selected for further studies. Then, the binding of these selected
peptide sequences to large unilamellar vesicles was studied by
comparing two separation methods: centrifugation and equilib-
rium dialysis. The same experiment was used to study the E1 pep-
tides inhibition capacity towards HIV-1 FP binding. The
thermodynamics of peptide-peptide interaction in solution was
also analyzed by isothermal titration calorimetry. Finally, the inhi-
bition effect was observed using a confocal microscopy.
As far as the lipid composition is concerned, whenever possible
we chose negatively charged phospholipids because it was found
that HIV-1 FP binds stronger to negative phospholipids than to li-
pid devoid of charge. The exception was the preparation of giant
unilamellar vesicles where a zwitterionic lipid was used but la-
beled with a negative probe, therefore giving a global negative
charge.
Our results indicate the capacity of certain peptide sequences of
the GBV-C E1 protein to inhibit the fusion process of liposomes in-
duced by the FP of the HIV-1 glycoprotein gp41.
2. Experimental
2.1. Materials
Amino acids and Rink amide resin (Tentagel R RAM, 0.19 meq/g)
were obtained from Novabiochem (Nottingham, UK). Dimethyl-
formamide (DMF) was purchased from Scharlau (Barcelona, Spain).
Dichloromethane (DCM) and piperidine were purchased from Flu-
ka (Neu-Ulm, Germany). Acetic acid, diethyl ether, and trifluoro-
acetic acid (TFA) were obtained from Merck (Poole, Dorset, UK).
N-hydroxybenzotriazole (HOBt) and N,N0-diisopropylcarbodiimide
(DIPCDI) coupling reagents were obtained from Fluka and Novabio-
chem, respectively. Other coupling reagents such as O-(7-azaben-
zotriazole-1-yl)-N, N,N0N0-tetramethyluronium hexafluorophos
phate (HATU) and N,N0-diisopropylethylenamine (DEIA) were ob-
tained from GenScript Corporation and Fluka, respectively. Scaveng-
ers such as ethanedithiol (EDT) and triisopropylsilane (TIS) were
obtained from Sigma–Aldrich.
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-pal-
mitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPG), and 1,2-
di-(9,10-dibromo) stearoyl-sn-glycero-3-phosphocholine (Br-PC)
and Rho-PE [(1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (ammonium salt) (18:1 lissamine
rhodamine PE)] were purchased from Avanti Polar Lipids. The
purity of these lipids was above 99% and they were used without
further purification.
Chloroform and methanol were purchased from Merck. Water
was double distilled and deionized (MilliQ system, Millipore)
(18.2 MO cm, pH 5.8). The buffer used in all experiments was HEPES
(from Sigma–Aldrich) 5 mM and NaCl (from Merck) 20 mM, pH 7.4.
2.2. Peptides synthesis
A scan of the GBV-C E1 protein (Genbank D90600, Japan) was
carried out by the semiautomatic multiple syntheses of 18-mer
peptides overlapped by fifteen residues. The resulting 58 linear
peptides were synthesized on a Multisyntech synthesizer using a
Tentagel R RAM resin (0.19 meq/g). This resin enables carboxamide
peptides to be obtained at the C-terminal end, by a solid phase
methodology following an Fmoc/tBu strategy by means of HATU
and DEIA activation. Side protection was effected by the following:
2,2,5,7,8-pentamethyl-chroman-6-sulfonyl (Pmc) for Arg, tert-Bu-
tyl (tBu) for Tyr, Ser, Thr and Asp and t-butyloxycarbonyl (Boc)
for Lys and Trp. Threefold molar excess of Fmoc-amino acids was
used throughout the synthesis. In the manual synthesis, the step-
wise addition of each residue was assessed by the Kaiser’s (ninhy-
drin) test [21] and repeated couplings were carried out when a
positive ninhydrin test was obtained.
The synthesized peptides were deprotected from the side-chain
groups and cleaved from the resin with a treatment of trifluoroace-
tic acid (TFA) containing appropriate proportions of scavengers
[22] such as H2O, triisopropylsilane (TIS), and ethanedithiol
(EDT): 94% TFA: 2.5% H2O: 2.5% EDT: 1% TIS.
Peptides were characterized using an analytical HPLC Perkin El-
mer with an LC-235 Diode Array Detector and a Binary LC Pump
250; the column used was a KROMASIL 100 C18 5 lm of
25  0.46 cm. The analysis was carried out using a linear gradient
of 95% H2O (0.05% TFA)/5% acetonitrile (0.05% TFA) to 5% H2O
(0.05% TFA)/95% acetonitrile (0.05% TFA). The characterization by
electrospray mass spectrometry was carried out using UPLC-MS
(AQUITY Ultra Performance LCTM from Waters, using a BEH C18
column of 1.7 lm, 2.1  100 mm). The peptides were purified to
as much as 90% by analytical HPLC at 215 nm (for further details
see Supporting information, Table 1).
Peptides synthesized manually (P7, P8, P10, P18 and P22) were
purified by semi-preparative HPLC in a Kromasil-C8 column and
characterized by ES–MS, achieving a final purity of over 95%.
The fusion peptide of the HIV-1 glycoprotein gp41, HIV-1 FP/
AVGIGALFLGFLGAAGSTMGAAS, was also synthesized by manual
SPPS but using a 100% polyethylene glycol-based ChemMatrix re-
sin that proved to be a more effective support for the solid-phase
synthesis of hydrophobic and highly structured peptides. The final
purity of the peptides achieved using HPLC was higher than 95%.
2.3. Preparation of lipid vesicles
2.3.1. Large unilamellar vesicles
Phospholipids were dissolved in a chloroform:methanol (2:1, v/
v) mixture and the solutions were evaporated to dryness in a vac-
uum with a rotary evaporator. The dried lipid film was subjected to
a high vacuum overnight to remove trace amounts of solvent.
Then, the lipid films were hydrated with Hepes buffer (5 mmol/L,
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pH 7.4) containing NaCl 20 mM to obtain multilamellar vesicles
(MLVs). MLVs were further transformed to large unilamellar
vesicles (LUVs) by extrusion under moderate pressure through a
polycarbonate filter of 0.1 lm pore size [23]. The lipid concentra-
tion of the stock solutions was 1.5 mM.
2.3.2. Giant unilamellar vesicles
Giant liposomes were made using the gentle hydration method
[24–26] of DMPC films doped with glucose [27] but with slight dif-
ferences in the preparation method.
Two solutions of (i) DMPC 10 mM in chloroform and (ii) glucose
20 mM in methanol were prepared. Solutions containing 50 lL of
DMPC and 250 lL of glucose were then mixed with 0.6% of Rho-
PE, which acted as a labeling probe to allow us to view the vesicles
during the confocal microscopy experiments. The mixture was
evaporated in the rotary evaporator to form the film and dried un-
der a nitrogen stream for 1 h. The dry lipid film was hydrated with
2 mL of distilled water and the liposomes left to grow at 40 C for
24 h. The cloud of vesicles formed was then collected.
2.4. Leakage of vesicular contents: ANTS/DPX assay
For the ANTS (8-aminonaphtalene-1,3,6-trisulfonic acid)-DPX
(N,N0-p-xylene-bis(pyridinium bromide) leakage assay [28,29],
approximately 20 mg of POPG was dissolved in a mixture of chlo-
roform and methanol (2:1), which was subsequently removed un-
der a stream of nitrogen. Approximately 2 mL of buffer was added
to the dry lipid. The buffer contained 12.5 mM ANTS and 45 mM
DPX from Molecular Probes (Eugene, OR) and 20 mM NaCl and
5 mM Hepes. The osmolarity of the ANTS/DPX solution was ad-
justed so that it was equal to that of the buffer in a cryoscopic
osmometer (Fiske One-ten). The suspension was frozen and
thawed 10 times to ensure maximum entrapment prior to extru-
sion [30]. A stock solution of LUV of approximately 0.1 lm in diam-
eter was formed by extrusion pressure through Nucleopore
polycarbonate membranes. The vesicles were separated from
unencapsulated material on Sephadex G-75 (Pharmacia, Uppsala,
Sweden), and equilibrated with 100 mM NaCl/5 mM Hepes buffer
(pH 7.4). The final concentration of the lipid was 0.1 mM.
Fluorescence was measured in an Aminco Bowman AB2 (Micro-
beam, SA) spectrofluorimeter before and after detergent was added.
Before being added to the suspension of LUVs, each GBV-C peptide
sequence corresponding to the E1 protein was incubated for
30 min with the HIV-1 FP in dimethylsulfoxide (DMSO). Following
this, the fluorescence was measured again. The amount of DMSO,
with respect to the total volume of the assay, was always less than
5%. No significant differences in fluorescence were observed when
adding the equivalent volume of DMSO in the absence of a peptide.
The dequenching of co-encapsulated ANTS and DPX fluorescence
resulting from dilution was measured to assess the leakage of aque-
ous contents from vesicles. Leakage was monitored by measuring
the increase in the ANTS/DPX fluorescence intensity at 520 nm, with
an excitation of 355 nm and slits of 8 nm. HIV-1 FP/E1 peptide ratios
ranged from 1/1 to 1/20. The percentage of leakage was calculated
according to the equation below:
%leakage ¼ ðF  F0ÞðF100  F0Þ
 100 ð1Þ
where F0 is the initial fluorescence of LUVs, F is the fluorescence
intensity after adding the peptide, and F100 is the fluorescence
intensity after the addition of 10 lL of a 10% (v/v) Triton-100 solu-
tion (complete lysis of LUVs).
2.5. Peptide binding to lipid vesicles
HPLC has been previously used for the determination of peptide
concentrations in the presence of LUV [31]. The column used was a
VYDAC 218TP54 C18 of 5 lm, 25  0.46 cm. The analysis was car-
ried out using a linear gradient of 95% H2O (0.05% TFA)/5% acetoni-
trile (0.05% TFA) to 5% H2O (0.05% TFA)/95% acetonitrile (0.05%
TFA) for 30 min and absorbance was monitored at 215 nm. Two
separation methods were used to determine the amount of peptide
bound to lipid vesicles.
2.5.1. Centrifugation method
The protocol developed by White et al. [32] was followed in this
study. Briefly, an aliquot of a mixture of peptide and liposomes is
centrifuged to separate peptides bound to the vesicles from those
that are unbound. Subsequently, the sediment holds the fraction
containing the peptide bound to the lipid vesicles, while the free
unbound peptide remains in the supernatant.
In order to facilitate vesicles sedimentation, we used LUVs made
with Br-PC, of which 20% was POPG. The brominated lipid is used
because it enables the liposomes in a centrifugal field to be sedi-
mented, and the negatively-charged lipid is required to facilitate
the highest interaction possible between the HIV-1 FP and the
liposomes.
Stock solutions of 1 mg ml1 of E1 peptides were used. Appro-
priate volumes of these peptides were selected to obtain a final
concentration of 0.2 mM in the final mixture with the brominated
liposomes. E1 peptides were incubated with the HIV-1 FP in DMSO
for a period of 30 min at a molar ratio HIV-1 FP:E1 peptide of 1:20.
The E1 peptides alone and the mixtures of both peptides were then
incubated with the brominated liposomes (0.565 mM) for a period
of 30 min; an aliquot of the lipid-peptide solution was withdrawn
for the HPLC analysis of total peptide and the samples were then
sedimented using a Microfuge 18 Centrifuge of Beckman Coul-
ter™. The sedimentation was done progressively by spinning at
4500, 9000 and then 16,000g for 30 min each time so that the lip-
osomes were sedimented gently at first and then spun into a tight
pellet. Following this, the peptide concentration of the supernatant
was analyzed by HPLC as described before.
2.5.2. Equilibrium dialysis
The basic principle of equilibrium dialysis is that two half cells,
one containing a small volume of lipid solution and the other con-
taining buffer, are separated by a membrane that is permeable to
peptides but impermeable to lipid vesicles. We used the RED (rapid
equilibrium dialysis) Device Inserts from Thermo Scientific and a
Teflon high-grade Reusable Base Plate. The sampling of total
and free peptide is done directly in an equilibrium dialysis, and
there is an explicit assumption that the free peptide has the same
concentration on both sides of the dialysis membrane [33].
To determine the incubation time necessary to achieve the
equilibrium, 200 lL of a solution of peptide 0.5 mg ml1 in DMSO
were added to the sample chamber and 350 lL of buffer were
added to the buffer sample. The device was then incubated at room
temperature at approximately 100 rpm on an orbital shaker. An
aliquot of each chamber was analyzed by HPLC after 4, 24 and 48 h.
To run the binding experiments, the E1 peptides were incubated
with HIV-1 FP, in a molar ratio of 1:20, and then with liposomes as
in the centrifugation assay, before adding them to the sample
chamber. After 48 h, the samples were analyzed by HPLC.
2.6. Isothermal titration calorimetry
Isothermal titration calorimetric (ITC) experiments were re-
corded on a VP-ITC micro-calorimeter (MicroCal, LLC, Northamp-
ton, MA). All the peptides were dissolved in DMSO. Briefly, a
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solution of 1 mg ml1 of E1 peptides was injected into the chamber
containing 25 lM HIV-1 FP. The calorimeter was first equilibrated
at 20 C, and the baseline was monitored during equilibration. The
time between injections was 10 min, and the stirring speed was
300 rpm. The heats of dilution were determined in control experi-
ments by injecting E1 peptides into DMSO. They were then sub-
tracted from the heats produced in the corresponding peptide–
peptide binding experiments. Control experiments were also per-
formed by titrating DMSO into HIV-1 FP. The total observed heat
effects were corrected for these small contributions. All titration
data were subsequently analyzed using the Origin 7 software (Mic-
roCal, LLC).
2.7. Confocal microscopy
Confocal microscopy studies were run to visualize how HIV-1
FP affected liposomes and to assess whether the E1 peptides were
capable of inhibiting the activity of HIV-1 FP. Experiments were
performed in an Olympus Fluoview (FV500) with an Olympus
IX70 microscopy associated.
Firstly, the HIV-1 FP was incubated during 30 min with E1 syn-
thetic peptides at different molar ratios, which were 1:1, 1:10 and
1:20. As the results for 1:10 and 1:20 were similar, the lower molar
ratio (1:10) was selected to run all the experiments, moreover, this
molar ratio also gave good results in the leakage of vesicular con-
tents assay. Following this, 50 lL of liposomes were added to this
mixture (1:10), 50 lL were added to HIV-1 FP alone and 50 lL of
liposomes were used as a control. Subsequently, the mixtures were
subjected to fixation with 3.2% of p-formaldehyde [34] to avoid the
aggregation of the liposomes.
3. Results and discussion
3.1. Leakage of vesicular contents: ANTS/DPX assay
After synthesizing 58 overlapped peptides of the envelope pro-
tein E1 of GBV-C, the initial proposed work was the study of their
capacity to inhibit the interaction and destabilization processes of
membranes, induced by HIV-1 FP. This was carried out using the
vesicular content leakage assay, as previously described for the
E2 GBV-C sequences [15].
The biophysical assay on the vesicle contents release [16,17,20]
was used to select the appropriate E1 GBV-C peptide sequences.
Firstly, HIV-1 was tested for its ability to induce leakage from large
unilamellar phospholipid vesicles (LUVs) of a defined composition.
POPG LUVs were used as it was previously reported that HIV-1
binds to negative phospholipids more strongly than to lipids with
no net charge [35].
For the assay, a stock solution of 1 mg ml1 of HIV-1 FP in DMSO
was used and E1 peptides were dissolved to a concentration of
0.2 mg ml1. The volume of HIV-1 FP solution providing approxi-
mately half of the total vesicle contents release was selected and
each GBV-C peptide sequence corresponding to the E1 protein
was incubated for 30 min with this concentration of HIV-1 FP.
The molar ratio was 1:20 and each experiment was repeated three
times.
We found that 53 peptides destabilized the membranes in the
same way as the fusion peptide. Only five of the peptides were
capable of inhibiting the vesicle contents leakage caused by HIV-
1 FP (Fig. 1a) at a molar ratio of 1:20 (HIV-1 FP:E1 peptide). These
peptides were named P7, P8, P10, P18 and P22, which correspond
to regions the E1(19-36), E1(22-39), E1(28-45), E1(52-69) and
E1(64-81), respectively.
Several ratios of the HIV-1 fusion peptide and these 5 peptides
(1:1, 1:2, 1:5, 1:10 and 1:20) were tested in the leakage assay. As
shown in Fig. 1b, when the proportions of the E1 peptides were
low, inhibition did not occur. Taking into account that the amount
of HIV-1 FP used provides approximately half of the total vesicle
contents release (horizontal red line), we observed that for P8
and P22 we needed a minimum molar ratio of 1:10 to decrease
the percentage leakage to under 50%. For P7, P10 and P18 a molar
ratio of 1:5 was enough to decrease the % leakage. Below these mo-
lar ratios, the leakage obtained was equal to the sum of the leakage
caused by the HIV-1 FP and by the E1 peptides.
Results found in this experiment indicate a dual behavior of the
peptides. In general, at low E1 peptide concentrations, leakage
caused by the HIV-1 FP is not inhibited but rather it increases as
a consequence of a synergism between the HIV-1 FP and E1 se-
quences. Above a certain molar ratio, depending on the peptide,
leakage is not completely but highly inhibited. These five peptides
were selected for the subsequent studies to corroborate their
capacity of inhibition of the vesicle contents leakage caused by
HIV-1 FP.
3.2. Peptide binding to lipid vesicles
3.2.1. Centrifugation method
For this assay a brominated phosphocholine (Br-PC) was re-
quired to ensure the separation of the liposome-peptide(s) com-
plex. The first question proposed was whether HIV-1 FP would
interact with liposomes composed of zwitterionic phospholipids
such as Br-PC, because HIV-1 FP binds more effectively to nega-
tively charged phospholipids. Therefore, we needed to know the
minimal amount of POPG in Br-PC liposomes that yielded the max-
imal percentage of leakage in the presence of HIV-1 FP. Thus, the
Fig. 1. (a) Inhibitory effect of E1 GBV-C peptides on HIV-1 FP induced leakage. The molar ratio of the HIV-1FP:E1 peptide is 1:20. (b) HIV-1 fusion peptide leakage in the
presence of P7,P8,P10,P18 and P22 at different molar ratios. E1 peptides were incubated with the HIV-1 FP amount that causes 50% of leakage (dotted line). Molar ratio POPG/
HIV-1 FP: 5/1. All experiments were repeated three times.
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first step was to repeat the leakage assay for the HIV-1 FP using lip-
osomes with different molar ratios of POPG and Br-PC.
The amount of HIV-1 FP that provided approximately half of the
total vesicle contents release of pure POPG vesicles was tested and
was used for all the phospholipid mixtures. The results are shown
in Fig. 2.
We found that the leakage of solutes from Br-PC vesicles was
low (approximately 15%), but increased more than 4-fold in the
presence of POPG. The leakage was similar for all POPG concentra-
tions, ranging from 20% to 100%. While this appears surprising
since charge interactions are believed to play a major role in the
peptide-lipid interactions that we have studied. However, the close
proximity of the POPG headgroups at high POPG concentrations
can shift the pKa of these headgroups, such that the fraction of
charged POPG lipids does not vary much above 20% POPG. Thus,
the mixture POPG:Br-PC 20:80 was selected for the binding exper-
iments, as it contains 20% POPG to ensure strong binding, as well as
80% Br-PC, to ensure the sedimentation of the liposomes upon cen-
trifugation. Liposomes were incubated with the peptides alone and
with mixtures of HIV-1 FP and E1 peptides.
The initial amount of peptide was analyzed by HPLC before cen-
trifugation. This value corresponded to the total concentration of
peptide added that can bind to LUVs. Free peptide or unbound pep-
tide concentration was measured under the same analytical condi-
tions from the supernatant after centrifugation. Each
determination was done in triplicate.
The results are shown in Table 1. For P7 and P18 when incu-
bated with HIV-1 FP, the percentage of E1 peptides bound in-
creased, while the percentage of bound HIV-1 FP decreased,
showing the inhibition of the interaction of HIV-1 FP with lipo-
somes. For P10 and P22 the percentage of bound E1 peptides de-
creased, as did the binding of HIV-1 FP to liposomes. The only
peptide that seemed to have no interaction with HIV-1 FP was
P8; as the activity of HIV-1 FP remained equal, it seems that P8
and HIV-1 FP act independently, in the same way as in the leakage
assay when a molar ratio of below 1:10 was used. Negative values
appeared when there was no binding (due to experimental errors).
The data obtained in this study allowed us to calculate the mole





where [P]total and [P]free are the aqueous peptide concentrations
measured before and after the centrifugation, respectively, and [L]
and [W] are the molar concentrations of lipid and water [32].
The results are shown in Table 2. We observed that the partition
coefficients of HIV-1 FP decreased when mixed with peptides that
inhibit its activity.
3.2.2. Equilibrium dialysis
We measured the time required to reach the equilibrium as ex-
plained above and found it to be 48 h for all samples. We then car-
ried out two series of experiments: firstly, we added the liposomes
to the sample cell that was the one that will contain the peptides
and secondly we added the liposomes to the buffer cell. In both
cases, after 48 h, the E1 peptides were equilibrated between the
sample cell and the buffer cell, indicating that there is no interac-
tion with the liposomes, independently of whether they are alone
or mixed with the fusion peptide.
In all cases, however, the amount of HIV-1 FP remaining with
the peptides was higher than in the buffer cell. The results ob-
tained are shown in Table 3. The values correspond to the average
of three determinations. We found that when the liposomes were
in the same cell as HIV-1 FP alone, it was not equilibrated, which
could mean that there is an interaction between HIV-1 FP and
the liposomes, forming a complex that could not pass through
the membrane. Thus, when HIV-1 FP was mixed with the E1 pep-
tides we could not deduce whether there was an interaction be-
tween them or whether it was simply bound to the liposomes.
Although for P18, the amount of HIV-1 FP remaining in the sample
cell was higher. When the liposomes were added to the buffer cell,
HIV-1 FP was equilibrated between both cells, except when in the
presence of the E1 peptides. This could be evidence of an interac-
tion between E1 peptides and HIV-1 FP in solution.
3.3. Isothermal titration calorimetry
To asses this interaction further, thermodynamic parameters
associated with the binding of E1 peptides to HIV-1 FP were deter-
mined by isothermal titration calorimetry (ITC). A binding curve
was then obtained from a plot of the heats from each injection
against the ratio of ligand and binding partner in the cell. There-
fore, the results from an ITC can provide an insight into the
Fig. 2. Percentage of leakage of vesicular contents (ANTS/DPX loaded LUVS) caused
by HIV-1 FP to liposomes with different molar ratios of POPG:Br-PC, expressed as
molar fraction of POPG. Each point is the average of at least three determinations.
Table 1
Percentage of bound E1 peptides in the presence and absence of HIV-1 FP bound to
POPG:Br-PC liposomes.
% Bound El peptide % Bound HIV-1 FP
HIV-1 FP 76.3 ± 0.2
P7 0.4 ± 0.1
P7 + HIV-1 FP 21.2 ± 0.0 8.0 ± 0.1
P8 22.8 ± 0.5
P8 + HIV-1 FP 19.9 ± 0.5 76.1 ± 0.4
P10 23.0 ± 0.6
P10 + HIV-1 FP 4.3 ± 0.4 38. ± 0.4
P18 1.7 ± 0.1
P18 + HIV-1 FP 12.7 ± 0.2 3.2 ± 0.2
Table 2
Mole fraction partition coefficients of E1 synthetic peptides and HIV-1 FP separately
and when mixed.
Kx (El peptides) Kx (HIV-1 FP)
P7 No binding
P7 + HIV-1 FP 6.43  105 2.04  105
P8 8.67  105
P8 + HIV-1 FP 5.75  105 7.50  106
P10 8.65  105
P10 + HIV-1 FP 6.45  104 9.34  105
P18 6.04  104
P18 + HIV-1 FP 2.12  105 4.89  104
P22 9.19  105
P22 + HIV-1 FP No binding 2.94  105
HIV-1 FP 4.68  106 4.68  106
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dominant forces associated with binding [19,36]. Due to the insol-
ubility of the HIV-1 FP, a microcalorimetry titration experiment
was performed using DMSO as a solvent. For P8 and P10 the system
did not reach saturation, while for P7, P18 and P22 the heat signal
diminished until only heats of dilution were observed. The corre-
sponding binding curves are shown in Fig. 3. The binding of P7,
P18 and P22 to HIV-1 FP was endothermic, indicated by positive
peaks. The hyperbolic titration curve demonstrates that the bind-
ing site of HIV-1 FP was saturated with the corresponding peptide
(Fig. 3 top). The cumulative reaction enthalpy as a function of the
peptide molar ratio is shown in Fig. 3 (bottom). The solid line cor-
responds to the best theoretical fit to the experimental data. The
binding enthalpy (DH) of the GBV-C peptides to the HIV-1 FP and
the entropy change (DS) are shown in Table 4.
This information provides insight into the dominant forces driv-
ing the association between E1 peptides and HIV-1 FP. The binding
of these peptides is strongly endothermic (DH positive) and bind-
ing is entropy-driven. The negative Gibbs energy (DG), defined as
DG = DH  T DS, indicates that the binding of these two peptides
is spontaneous. The binding stoichiometry (N) of E1 peptides to
HIV-1 FP is approximately 1:1 for P18 and P22 and 2:1 for P7.
Table 3
Percentage of HIV-1 FP incubated with E1 peptides in a molar ratio of 1:20 present
after 48 h of equilibrium dialysis. Experiments were carried out by adding the
liposomes to the same cell of HIV-1 FP (sample cell) and then adding them separately.









P7 83.7 ± 0.4 16.3 ± 0.1 62.5 ± 0.6 34.8 ± 0.3
P8 87.9 ± 0.4 12.1 ± 0.4 74.7 ± 0.4 25.3 ± 0.1
P10 73.4 ± 0.3 26.6 ± 0.2 67.1 ± 0.4 32.9 ± 0.4
P18 92.5 ± 0.1 7.5 ± 0.2 81.2 ± 0.5 18.8 ± 0.4
P22 85.2 ± 0.0 14.8 ± 0.4 78.6 ± 0.3 21.4 ± 0.2
HIV-1 FP 82.5 ± 0.1 17.5 ± 0.3 50.6 ± 0.4 49.4 ± 0.3
Table 4








P7 3.21 ± 0.34 10.46 0.47 ± 0.04 2.03 ± 0.46  105 4.93
P18 9.32 ± 0.81 15.646 0.73 ± 0.05 4.33 ± 0.30  104 23.1
P22 9.60 ± 0.40 16.09 0.88 ± 0.03 6.12 ± 0.31  104 16.3
N = Stoichiometry; Ka = association constant; Kd = dissociation constant.
Fig. 3. Isothermal titration calorimetry results for the E1 synthetic peptides/HIV-1 FP interaction. Each figure corresponds to a different E1 peptide: a = P7, b = P18 and
c = P22.
Fig. 4. Confocal microscopy images of (a) DMPC GUVs, (b) DMPC GUVs mixed with HIV-1 FP, showing broken liposomes and (c)DMPC GUVs mixed with HIV-1 FP, showing
the fusion between two vesicles.
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3.4. Confocal microscopy
Giant vesicles are often used in biological research not only be-
cause their properties are similar to those of cell membranes [27],
but also because of the size of the membrane model systems,
which enables visualization by optical microscopy and microma-
nipulation of individual vesicles [37].
Rodriguez et al. [37] proved that the charge has an important
influence on the vesicle formation, showing that the yield of clean
unilamellar vesicles decreases when the amount of charged lipid is
above 10%. Since Rhodamine-PE is negatively charged, DMPC was
chosen as a neutral phospholipid for preparing giant vesicles; PC,
however, is a chief component of the cell membrane. We obtained
vesicles from 10 to 50 lm. Firstly, HIV-1 FP was added to the ves-
icles. We then observed the appearance of elongated structures,
corresponding to broken liposomes (Fig 4b). In addition, we saw
that HIV-1 FP favored membrane fusion, shown in Fig. 4c.
HIV-1 FP was incubated with E1 synthetic peptides before add-
ing them to the liposomes solution. The images in Fig. 5 show that
GUVs are intact and therefore stable in the presence of the peptides
mixture.
Confocal microscopy revealed what happens to the membranes
when mixed with HIV-1 FP, providing additional evidence of the
inhibiting activity of these five peptides, which correspond to the
structural protein E1 of GBV-C.
4. Conclusions
We found five GBV-C related peptides with the ability to inhibit
the interaction of the HIV-1 fusion peptide with model
membranes.
When E1 peptides were mixed with HIV-1 FP, we observed dif-
ferent behaviors. On the one hand, some E1 peptides such as P7
and P18 increased their binding with liposomes in the presence
of HIV-1 FP. We also found that less HIV-1 FP was bound to lipo-
somes than when it was not mixed with peptides. In contrast,
P10 and P22 decreased their binding to liposomes also reducing
the percentage of HIV-1 FP bound to liposomes; P8 did not inhibit
HIV-1 FP binding to liposomes, but the leakage assay revealed an
inhibition of the pore formation caused by HIV-1 FP. Moreover,
the dialysis experiments revealed that the percentage of HIV-1 FP
remaining with E1 peptides was higher than the percentage
remaining with the liposomes. Confocal microscopy revealed sim-
ilar inhibition activity for all of E1 peptides.
Each peptide has a different behavior in the presence of HIV-1
FP. Equilibrium dialysis experiments indicate that the peptides
interact in solution, which was corroborated by ITC experiments
for P7, P18 and P22. However, we could not confirm the same for
the other peptides. Additional assays for P8 and P10 should be car-
ried out to understand how they interact with HIV-1 FP.
The different results obtained could indicate that HIV-1 FP and
these peptides interact in different ways. The different methods
that we used provide different glimpses of their behavior. There
is evidence that the interactions are complex. It appears that the
peptides are not interacting on the membrane only or in solution.
Thus, the exact mechanism behind the interaction needs to be
investigated further.
Thus, these peptides could be involved in the prevention of HIV-
1 entry by binding to the HIV-1 FP. In order to test the use of this
peptide as an antiviral therapeutic agent, other assays are currently
being performed.
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Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.jcis.2011.04.053.
Fig. 5. Confocal microscopy images of DMPC GUVs mixed with HIV-1 FP, which was incubated with E1 synthetic peptides: P7 (a), P8 (b), P10 (c), P18 (d), and P22 (e).
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